Revenio Group Oyj (LON:0KFH)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 326.96M -41.9% |
| Revenue (ttm) | 96.96M +4.4% |
| Net Income | 13.72M -17.7% |
| EPS | 0.51 -17.7% |
| Shares Out | n/a |
| PE Ratio | 23.83 |
| Forward PE | 16.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34 |
| Open | 14.08 |
| Previous Close | 13.64 |
| Day's Range | 14.08 - 14.46 |
| 52-Week Range | 11.88 - 24.56 |
| Beta | 1.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 8, 2026 |
About Revenio Group Oyj
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by vet... [Read more]
Financial Performance
In 2025, Revenio Group Oyj's revenue was 109.85 million, an increase of 5.80% compared to the previous year's 103.82 million. Earnings were 17.41 million, a decrease of -5.87%.
Financial numbers in EUR Financial StatementsNews
Revenio Group Oyj Earnings Call Transcript: Q1 2026
Q1 saw 8.4% FX-adjusted sales growth, strong U.S. and Europe performance, but lower operating profit due to Visionix transaction costs. The Visionix acquisition expands the addressable market and product portfolio, with significant synergies and a rights issue planned for H2.
Revenio Group Oyj Quarterly report: Q1 2026
Revenio Group Oyj has published its Q1 2026 quarterly earnings report on April 28, 2026.
Revenio Group Oyj Slides: Q1 2026
Revenio Group Oyj has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Revenio Group Oyj Transcript: M&A announcement
The merger creates a leading ophthalmic diagnostics company with a EUR 2.5 billion accessible market, targeting EUR 20 million in synergies and 25% EBITDA margin by 2028-2029. Integration is structured for rapid synergy capture, with strong shareholder and leadership commitment.
Revenio Group Oyj Slides: M&A announcement
Revenio Group Oyj has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Revenio Group Oyj Press release: M&A announcement
Revenio Group Oyj issued a press release on April 13, 2026, disclosing material business information to investors.
Revenio Group Oyj Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong sales growth, especially in the US and EMEA, with robust cash flow and expanding screening solutions. 2026 guidance projects 8%-15% net sales growth, with profitability supported by price increases and ongoing R&D, despite tariff and clinical trial cost headwinds.
Revenio Group Oyj Annual report: Q4 2025
Revenio Group Oyj has published its Q4 2025 annual report on February 11, 2026.
Revenio Group Oyj Quarterly report: Q4 2025
Revenio Group Oyj has published its Q4 2025 quarterly earnings report on February 11, 2026.
Revenio Group Oyj Slides: Q4 2025
Revenio Group Oyj has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 11, 2026.
Revenio Group Oyj Earnings Call Transcript: Q3 2025
Q3 delivered 8.1% sales growth and 9.1% higher operating profit, driven by strong European and U.S. demand for screening solutions. Guidance is unchanged, with Q4 expected to be the strongest quarter. APAC lagged due to currency headwinds, while new product launches and M&A activity continued.
Revenio Group Oyj Quarterly report: Q3 2025
Revenio Group Oyj has published its Q3 2025 quarterly earnings report on October 30, 2025.
Revenio Group Oyj Slides: Q3 2025
Revenio Group Oyj has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 30, 2025.